New research suggests that individuals who discontinue new weight-loss injections like Mounjaro or Wegovy can put back on shed pounds much more quickly than those who stop conventional lifestyle regimens.
Research printed in a leading medical journal demonstrates that while overweight people often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month once they quit.
"People buying these treatments must be cognizant of the potential of fast rebound weight gain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
This pace of recovery implies a return to original weight in about one and a half years.
Weighing Therapies
The study, which reviewed dozens of studies involving thousands of participants, compared the results of these new drugs with older methods.
Researchers emphasize that individuals who lose weight through lifestyle changes alone generally have a less rapid creep back—approximately 0.1 kg a month—post-intervention.
Understanding the Quick Rebound
Doctors believe the way of the jabs is key to understanding the accelerated weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to produce less of its own natural hormone, and may also reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in appetite is uncontrolled, making excessive eating a significant risk."
A Chronic Issue?
The NHS recommend the jabs for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians contend that, due to the significant potential of weight regain, the treatment is often life-long.
This opinion is reinforced by drug manufacturers, who note that the results "highlight the chronic character of excess weight," similar to managing diseases like hypertension.
User Accounts
People who have discontinued the jabs report a intense resurgence of cravings.
"It felt as if a switch flipping and you become ravenous," described one woman.
This difficulty is compounded if patients have not established sustainable dietary or behavioural changes during treatment.
Widespread Adoption
Survey data indicate that millions of adults in the UK have tried these injections in the past year, with interest being substantial.
- Adoption is higher among women compared to males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a magic fix and long-term success relies on integrated behavioural support.
